Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sgn-stnv
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SGN-STNV is an investigational antibody-drug conjugate (ADC) designed to target the tumor-associated carbohydrate antigen Sialyl Thomsen-nouveau (STn), which is highly expressed on a variety of solid tumors. The ADC consists of an anti-STn monoclonal antibody linked to the cytotoxic agent monomethyl auristatin E (MMAE) via the MC-vc-PAB linker. Upon binding to STn-expressing cancer cells, SGN-STNV delivers MMAE intracellularly, disrupting microtubule function and inducing cell death. The drug was initially developed by Seagen and later taken up by Pfizer for clinical development. It has been evaluated in Phase 1 trials for multiple advanced solid tumors, including ovarian cancer, endometrial carcinoma, pseudomyxoma peritonei, non-small cell lung cancer (NSCLC), HER2-negative breast cancer, cervical cancer, colorectal cancer, esophageal and gastric cancers, gastroesophageal junction carcinoma, exocrine pancreatic adenocarcinoma, and appendiceal adenocarcinoma.
- Other names
- anti-STn antibody-drug conjugate SGN-STNV
02
Targets
TUBB (Tubulin (alpha and beta subunits))STn-MUC1 (Sialyl-Tn-MUC1)
Beyond the preview
Go deeper on sgn-stnv.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sgn-stnv.